vs
Ernexa Therapeutics Inc.（ERNA）与RAPT Therapeutics, Inc.（RAPT）财务数据对比。点击上方公司名可切换其他公司
Ernexa Therapeutics Inc.自由现金流更多（$-16.2M vs $-21.9M）
Ernexa Therapeutics Inc.是一家总部位于美国的临床阶段生物技术企业，专注于开发针对存在高度未满足医疗需求的罕见神经内分泌、代谢类疾病的新型靶向疗法，致力于为缺乏有效治疗方案的患者群体提供新选择。
Horizon Therapeutics plc是一家生物制药企业，专注于罕见病和风湿性疾病相关药物的研发、生产及商业化，致力于满足相关患者的迫切治疗需求。其产品主要在美国市场销售，2019年美国市场营收占全球总营收的97%，2023年10月被安进公司收购。
ERNA vs RAPT — 直观对比
营收规模更大
ERNA
是对方的Infinity倍
$0
自由现金流更多
ERNA
多$5.7M
$-21.9M
损益表 — Q4 FY2024 vs Q3 FY2023
| 指标 | | |
|---|---|---|
| 营收 | $1.0K | $0 |
| 净利润 | — | $-31.4M |
| 毛利率 | 100.0% | — |
| 营业利润率 | — | — |
| 净利率 | — | — |
| 营收同比 | — | — |
| 净利润同比 | 6.4% | -47.7% |
| 每股收益（稀释后） | — | $-0.82 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ERNARAPT
| Q4 24 | $1.0K | — | ||
| Q3 24 | $487.0K | — | ||
| Q2 24 | $47.0K | — | ||
| Q1 24 | $47.0K | — | ||
| Q3 23 | $51.0K | $0 | ||
| Q2 23 | — | $0 | ||
| Q1 23 | $0 | — | ||
| Q4 22 | — | $0 |
净利润ERNARAPT
| Q4 24 | — | — | ||
| Q3 24 | $-26.6M | — | ||
| Q2 24 | $-5.5M | — | ||
| Q1 24 | $-6.6M | — | ||
| Q3 23 | $-5.6M | $-31.4M | ||
| Q2 23 | — | $-25.3M | ||
| Q1 23 | $-5.4M | — | ||
| Q4 22 | — | $-23.0M |
毛利率ERNARAPT
| Q4 24 | 100.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
营业利润率ERNARAPT
| Q4 24 | — | — | ||
| Q3 24 | -463.9% | — | ||
| Q2 24 | -10491.5% | — | ||
| Q1 24 | -12312.8% | — | ||
| Q3 23 | -10794.1% | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
净利率ERNARAPT
| Q4 24 | — | — | ||
| Q3 24 | -5462.8% | — | ||
| Q2 24 | -11763.8% | — | ||
| Q1 24 | -14142.6% | — | ||
| Q3 23 | -10962.7% | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
每股收益（稀释后）ERNARAPT
| Q4 24 | — | — | ||
| Q3 24 | $-73.70 | — | ||
| Q2 24 | $-15.34 | — | ||
| Q1 24 | $-1.23 | — | ||
| Q3 23 | $-1.03 | $-0.82 | ||
| Q2 23 | — | $-0.66 | ||
| Q1 23 | $-1.06 | — | ||
| Q4 22 | — | $-0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.7M | $184.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.7M | $172.8M |
| 总资产 | $5.3M | $199.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ERNARAPT
| Q4 24 | $1.7M | — | ||
| Q3 24 | $4.3M | — | ||
| Q2 24 | $2.6M | — | ||
| Q1 24 | $5.1M | — | ||
| Q3 23 | $4.6M | $184.8M | ||
| Q2 23 | — | $205.0M | ||
| Q1 23 | $5.4M | — | ||
| Q4 22 | — | $249.1M |
股东权益ERNARAPT
| Q4 24 | $1.7M | — | ||
| Q3 24 | $-45.4M | — | ||
| Q2 24 | $-8.5M | — | ||
| Q1 24 | $-3.4M | — | ||
| Q3 23 | $3.6M | $172.8M | ||
| Q2 23 | — | $199.7M | ||
| Q1 23 | $7.4M | — | ||
| Q4 22 | — | $245.2M |
总资产ERNARAPT
| Q4 24 | $5.3M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $46.5M | — | ||
| Q1 24 | $49.7M | — | ||
| Q3 23 | $52.2M | $199.7M | ||
| Q2 23 | — | $220.8M | ||
| Q1 23 | $15.1M | — | ||
| Q4 22 | — | $266.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-21.9M |
| 自由现金流经营现金流 - 资本支出 | $-16.2M | $-21.9M |
| 自由现金流率自由现金流/营收 | -1620500.0% | — |
| 资本支出强度资本支出/营收 | 36900.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-28.9M | $-91.1M |
8季度趋势，按日历期对齐
经营现金流ERNARAPT
| Q4 24 | $-15.8M | — | ||
| Q3 24 | $-6.3M | — | ||
| Q2 24 | $-2.3M | — | ||
| Q1 24 | $-3.7M | — | ||
| Q3 23 | $-5.8M | $-21.9M | ||
| Q2 23 | — | $-28.8M | ||
| Q1 23 | $-6.0M | — | ||
| Q4 22 | — | $-22.8M |
自由现金流ERNARAPT
| Q4 24 | $-16.2M | — | ||
| Q3 24 | $-6.3M | — | ||
| Q2 24 | $-2.5M | — | ||
| Q1 24 | $-3.8M | — | ||
| Q3 23 | — | $-21.9M | ||
| Q2 23 | — | $-29.0M | ||
| Q1 23 | — | — | ||
| Q4 22 | — | $-22.9M |
自由现金流率ERNARAPT
| Q4 24 | -1620500.0% | — | ||
| Q3 24 | -1294.5% | — | ||
| Q2 24 | -5336.2% | — | ||
| Q1 24 | -8187.2% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
资本支出强度ERNARAPT
| Q4 24 | 36900.0% | — | ||
| Q3 24 | 3.9% | — | ||
| Q2 24 | 529.8% | — | ||
| Q1 24 | 214.9% | — | ||
| Q3 23 | 0.0% | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
